Does the media prefer KRYS or ALNY?

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BIIB or KRYS?

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.24 $1.29B $5.65 38.43 Krystal Biotech $389.13M 26.40 $204.83M $7.98 43.48

Is BIIB or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Krystal Biotech 54.82% 19.34% 17.65%

Does the media favor BIIB or KRYS?

In the previous week, Biogen had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 11 mentions for Biogen and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Biogen's score of 1.10 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, INSM or KRYS?

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 46.60 -$1.28B -$4.11 N/A Krystal Biotech $389.13M 26.40 $204.83M $7.98 43.48

Is INSM or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Insmed's net margin of -76.94%. Krystal Biotech's return on equity of 19.34% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Krystal Biotech 54.82% 19.34% 17.65%

Does the media refer more to INSM or KRYS?

In the previous week, Insmed had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 11 mentions for Insmed and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Insmed's score of 1.15 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or KRYS?

In the previous week, BioNTech had 15 more articles in the media than Krystal Biotech. MarketBeat recorded 21 mentions for BioNTech and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat BioNTech's score of 0.44 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, INCY or KRYS?

Incyte has higher revenue and earnings than Krystal Biotech. Incyte is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.82B 4.23 $1.29B $7.85 15.47 Krystal Biotech $389.13M 26.40 $204.83M $7.98 43.48

Is INCY or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Krystal Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Krystal Biotech 54.82% 19.34% 17.65%

Does the media favor INCY or KRYS?

In the previous week, Incyte had 13 more articles in the media than Krystal Biotech. MarketBeat recorded 19 mentions for Incyte and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Incyte's score of 0.98 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Krystal Biotech (KRYS) Competitors

$347.00 +1.45 (+0.42%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$348.84 +1.83 (+0.53%)

As of 09/11/2026 07:30 PM Eastern

Compare

KRYS vs. ALNY, BIIB, INSM, BNTX, and INCY

Should you buy Krystal Biotech stock or one of its competitors? Krystal Biotech's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Insmed (INSM), BioNTech (BNTX), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Krystal Biotech (NASDAQ:KRYS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Krystal Biotech has a net margin of 54.82% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Krystal Biotech has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Krystal Biotech. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech presently has a consensus target price of $365.40, indicating a potential upside of 5.30%. Alnylam Pharmaceuticals has a consensus target price of $376.67, indicating a potential upside of 51.47%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Alnylam Pharmaceuticals beats Krystal Biotech on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Biogen?

Biogen (NASDAQ:BIIB) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Biogen had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 11 mentions for Biogen and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Biogen's score of 1.10 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biogen currently has a consensus target price of $230.14, suggesting a potential upside of 5.98%. Krystal Biotech has a consensus target price of $365.40, suggesting a potential upside of 5.30%. Given Biogen's higher probable upside, equities analysts plainly believe Biogen is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Krystal Biotech beats Biogen on 10 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Insmed?

Insmed (NASDAQ:INSM) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Insmed presently has a consensus target price of $205.52, indicating a potential upside of 58.81%. Krystal Biotech has a consensus target price of $365.40, indicating a potential upside of 5.30%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Insmed is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Insmed has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Insmed's net margin of -76.94%. Krystal Biotech's return on equity of 19.34% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Insmed had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 11 mentions for Insmed and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Insmed's score of 1.15 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	46.60	-$1.28B	-$4.11	N/A
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48

Summary

Krystal Biotech beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Krystal Biotech has a net margin of 54.82% compared to BioNTech's net margin of -63.54%. Krystal Biotech's return on equity of 19.34% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, BioNTech had 15 more articles in the media than Krystal Biotech. MarketBeat recorded 21 mentions for BioNTech and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat BioNTech's score of 0.44 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.23	-$1.29B	-$7.83	N/A
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48

BioNTech presently has a consensus price target of $126.00, suggesting a potential upside of 30.26%. Krystal Biotech has a consensus price target of $365.40, suggesting a potential upside of 5.30%. Given BioNTech's higher probable upside, equities analysts plainly believe BioNTech is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Krystal Biotech beats BioNTech on 10 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Incyte?

Incyte (NASDAQ:INCY) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Incyte has higher revenue and earnings than Krystal Biotech. Incyte is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48

97.0% of Incyte shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Krystal Biotech has a net margin of 54.82% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Incyte had 13 more articles in the media than Krystal Biotech. MarketBeat recorded 19 mentions for Incyte and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat Incyte's score of 0.98 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte currently has a consensus price target of $124.05, indicating a potential upside of 2.12%. Krystal Biotech has a consensus price target of $365.40, indicating a potential upside of 5.30%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Incyte has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Summary

Incyte beats Krystal Biotech on 9 of the 16 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.23B	$3.86B	$7.15B	$12.71B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	43.48	14.11	272.98	25.27
Price / Sales	26.40	1,449.22	646.20	90.55
Price / Cash	47.40	106.68	77.04	51.44
Price / Book	8.25	15.13	10.33	6.20
Net Income	$204.83M	-$22.82M	$3.49B	$358.27M
7 Day Performance	-3.14%	-4.31%	-3.33%	-2.36%
1 Month Performance	4.25%	0.00%	-0.42%	-2.77%
1 Year Performance	141.51%	40.67%	19.22%	7.64%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	3.1536 of 5 stars	$347.00 +0.4%	$365.40 +5.3%	+140.4%	$10.23B	$389.13M	43.48	295	Positive News
ALNY Alnylam Pharmaceuticals	4.4564 of 5 stars	$266.11 flat	$386.14 +45.1%	-46.9%	$35.61B	$3.71B	49.46	2,770	Analyst Forecast Gap Down
BIIB Biogen	3.2646 of 5 stars	$220.83 flat	$228.50 +3.5%	+45.9%	$32.63B	$9.89B	39.08	7,500	Positive News Analyst Forecast
INSM Insmed	3.42 of 5 stars	$126.29 flat	$205.52 +62.7%	-11.2%	$27.58B	$606.42M	N/A	1,664	News Coverage Positive News Insider Trade
BNTX BioNTech	4.2576 of 5 stars	$103.76 flat	$126.00 +21.4%	-7.3%	$26.24B	$3.25B	N/A	7,807	Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. ALNY, BIIB, INSM, BNTX, and INCY

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Summary

How does Krystal Biotech compare to Biogen?

Summary

How does Krystal Biotech compare to Insmed?

Summary

How does Krystal Biotech compare to BioNTech?

Summary

How does Krystal Biotech compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. ALNY, BIIB, INSM, BNTX, and INCY

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Is KRYS or ALNY more profitable?

Do insiders and institutionals have more ownership in KRYS or ALNY?

Which has more volatility & risk, KRYS or ALNY?

Which has better valuation and earnings, KRYS or ALNY?

Does the media prefer KRYS or ALNY?

Do analysts rate KRYS or ALNY?

Summary

How does Krystal Biotech compare to Biogen?

Which has more risk and volatility, BIIB or KRYS?

Which has stronger earnings & valuation, BIIB or KRYS?

Is BIIB or KRYS more profitable?

Does the media favor BIIB or KRYS?

Do institutionals and insiders hold more shares of BIIB or KRYS?

Do analysts prefer BIIB or KRYS?

Summary

How does Krystal Biotech compare to Insmed?

Do analysts prefer INSM or KRYS?

Which has more risk & volatility, INSM or KRYS?

Is INSM or KRYS more profitable?

Does the media refer more to INSM or KRYS?

Do institutionals & insiders believe in INSM or KRYS?

Which has better earnings & valuation, INSM or KRYS?

Summary

How does Krystal Biotech compare to BioNTech?

Is BNTX or KRYS more profitable?

Does the media prefer BNTX or KRYS?

Which has better earnings & valuation, BNTX or KRYS?

Do analysts prefer BNTX or KRYS?

Which has more volatility & risk, BNTX or KRYS?

Do institutionals and insiders hold more shares of BNTX or KRYS?

Summary

How does Krystal Biotech compare to Incyte?

Which has stronger valuation & earnings, INCY or KRYS?

Do insiders & institutionals believe in INCY or KRYS?

Is INCY or KRYS more profitable?

Does the media favor INCY or KRYS?

Do analysts recommend INCY or KRYS?

Which has more risk and volatility, INCY or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools